1. Home
  2. MOV vs RIGL Comparison

MOV vs RIGL Comparison

Compare MOV & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Movado Group Inc.

MOV

Movado Group Inc.

HOLD

Current Price

$27.87

Market Cap

568.3M

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$30.33

Market Cap

628.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOV
RIGL
Founded
1961
1996
Country
United States
United States
Employees
1386
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
568.3M
628.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
MOV
RIGL
Price
$27.87
$30.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$31.50
$45.67
AVG Volume (30 Days)
125.5K
310.7K
Earning Date
05-28-2026
05-05-2026
Dividend Yield
5.05%
N/A
EPS Growth
N/A
1867.68
EPS
N/A
19.48
Revenue
N/A
$294,282,000.00
Revenue This Year
$1.92
N/A
Revenue Next Year
$0.67
$12.75
P/E Ratio
$25.52
$1.56
Revenue Growth
N/A
64.15
52 Week Low
$13.71
$16.88
52 Week High
$29.24
$52.24

Technical Indicators

Market Signals
Indicator
MOV
RIGL
Relative Strength Index (RSI) 61.71 50.92
Support Level $22.95 $28.08
Resistance Level N/A $31.26
Average True Range (ATR) 0.75 1.33
MACD 0.15 0.17
Stochastic Oscillator 72.35 53.27

Price Performance

Historical Comparison
MOV
RIGL

About MOV Movado Group Inc.

Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: